By employing the CellMineTM database, we found that RNF43 expression was significantly correlated with the sensitivity of several drugs that have been widely applied in cancer clinical treatment or clinical trials, such as cisplatin, erlotinib, cobimetinib, and everolimus. The gene discussed is RNF43; the disease is cancer.